Vistarin
Generic Name
Vistarin 6000 Anti-Xa Injection
Manufacturer
MediPharm Corp.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vistarin 6000 anti xa injection | ৳ 575.00 | N/A |
Description
Overview of the medicine
Vistarin 6000 Anti-Xa Injection is a low molecular weight heparin (LMWH) used to prevent and treat various thromboembolic disorders. It specifically targets Factor Xa to inhibit clot formation.
Uses & Indications
Dosage
Adults
For VTE prophylaxis: 6000 Anti-Xa IU (0.6 mL) once daily subcutaneously. For DVT/PE treatment: 6000 Anti-Xa IU (0.6 mL) twice daily subcutaneously or as directed by physician.
Elderly
No specific dose adjustment is usually required based on age alone, but renal function should be monitored.
Renal_impairment
Severe renal impairment (CrCl < 30 mL/min): Dose reduction or extended dosing interval may be necessary. Monitor anti-Xa levels.
How to Take
Administer subcutaneously into the abdominal wall, thigh, or upper arm. Do not inject intramuscularly. Alternate injection sites. Do not expel the air bubble from the pre-filled syringe before injection.
Mechanism of Action
Vistarin 6000 Anti-Xa binds to antithrombin III (ATIII) and enhances its inhibitory activity against activated Factor Xa (FXa), thereby preventing the formation of thrombin and subsequent clot formation. It has a higher anti-Xa to anti-IIa ratio compared to unfractionated heparin.
Pharmacokinetics
Onset
Within 1-2 hours after subcutaneous injection.
Excretion
Primarily renal excretion of intact drug and metabolites. Dosage adjustment is required in severe renal impairment.
Half life
Approximately 4-6 hours (anti-Xa activity) after a single subcutaneous dose, which can be prolonged in renal impairment.
Absorption
Rapid and complete absorption after subcutaneous (SC) administration, with peak anti-Xa activity achieved within 3-5 hours.
Metabolism
Partially depolymerized in the liver to smaller fragments, some with retained anti-Xa activity.
Side Effects
Contraindications
- •Active major bleeding
- •History of heparin-induced thrombocytopenia (HIT) with or without thrombosis
- •Hypersensitivity to the active substance or any excipients
- •Acute bacterial endocarditis
- •Spinal/epidural anesthesia or lumbar puncture in patients on therapeutic anticoagulation due to risk of spinal hematoma
Drug Interactions
Dextran
Increased risk of bleeding.
NSAIDs (Ibuprofen, Naproxen)
Increased risk of gastrointestinal bleeding. Use with caution.
Oral Anticoagulants (Warfarin, NOACs)
Increased risk of bleeding. Close monitoring and bridging therapy required.
Antiplatelet Agents (Aspirin, Clopidogrel)
Increased risk of bleeding. Concomitant use should be with caution.
Storage
Store below 30°C. Do not freeze. Protect from light. Keep out of reach of children.
Overdose
Symptoms include bleeding. Management involves discontinuing the drug. Protamine sulfate can partially neutralize the anti-Xa effect if severe bleeding occurs, but it primarily neutralizes anti-IIa activity.
Pregnancy & Lactation
Pregnancy Category B (for some LMWHs). Use during pregnancy only if clearly needed. LMWHs do not generally pass into breast milk in significant amounts. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patent expired for generic versions
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
